中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Value of combined measurement of hepatitis B virus covalently closed circular DNA,HBsAg,and hepatitis B virus pregenomic RNA in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with entecavir

DOI: 10.3969/j.issn.1001-5256.2020.05.012
Research funding:

 

  • Received Date: 2019-11-20
  • Published Date: 2020-05-20
  • Objective To investigate value of combined measurement of serum hepatitis B virus(HBV) covalently closed circular DNA(cccDNA), HBsAg, and HBV pregenomic RNA(pgRNA) in predicting the treatment outcome of HBeAg-positive chronic hepatitis B(CHB) patients treated with entecavir(ETV).Methods A total of 87 HBeAg-positive CHB patients who were diagnosed and treated inThe Second Affiliated Hospital of Suzhou University from May 2015 to May 2017 were enrolled. All patients were treated with ETV for 48 weeks, and the serum levels of HBV cccDNA, HBsAg, and HBV pgRNA were measured at baseline and at weeks 12, 24, and 48 of treat-ment. Thet-test was used for comparison of normally distributed continuous data between groups, and the Mann-WhitneyUtest was usedfor comparison of non-normally distributed continuous data between groups. The chi-square test was used for comparison of categorical da-ta between groups, and the Mann-WhitneyUtest was used for comparison of ranked data between groups. A Pearson correlation analysiswas performed to determine the correlation of liver HBV cccDNA with serum HBsAg and HBV pgRNA. A multivariate logistic regression analysis was used to investigate the predictive factors for complete response, and the receiver operating characteristic(ROC) curve was usedto evaluate the value of serum HBV cccDNA, HBsAg, and HBV pgRNA measured alone or in combination in predicting complete response.Results Of all 87 HBeAg-positive CHB patients after 48 weeks of ETV treatment, 38 achieved complete response and 49 did not achievecomplete response. Compared with the non-complete response group, the complete response group had significant reductions in the levels ofHBV cccDNA at baseline and at weeks 24 and 48 of treatment(Z =-2. 452,-2. 518, and-2. 266, allP< 0. 001), HBsAg at baselineand at weeks 12, 24, and 48 of treatment(Z=-2. 431,-2. 750,-2. 386, and-2. 536, allP< 0. 001), and HBV pgRNA at weeks12, 24, and 48 of treatment(Z=-2. 674,-2. 503, and-2. 528, allP< 0. 001). Compared with the non-complete response group,the complete response group had significantly greater reductions in HBV cccDNA at week 24 of treatment, HBsAg at week 12 of treatment,and HBV pgRNA at week 12 of treatment(Z=-2. 352,-2. 566, and-2. 389,P= 0. 006, 0. 001, and 0. 004). Serum HBsAg andHBV pgRNA were positively correlated with HBV cccDNA in liver tissue(r= 0. 553 and 0. 757, bothP< 0. 001). The levels of HBVcccDNA at week 24 of treatment(odds ratio [OR] = 6. 248, 95% confidence interval [CI]: 1. 574-14. 262,P< 0. 05), HBsAg at week12 of treatment(OR = 5. 452, 95% CI: 2. 048-16. 888,P< 0. 05), and HBV pgRNA at week 12 of treatment(OR = 5. 670, 95% CI:1. 201-16. 183,P< 0. 05) were predictive factors for complete response. As for the area under the ROC curve(AUC), HBV cccDNA,HBsAg, or HBV pgRNA measured alone had a significantly lower AUC than the combined measurement of the three indices(0. 845/0. 741/0. 773 vs 0. 913, allP< 0. 001), and the patients with a value of < 9. 7 could achieve complete response at week 48 of treatment.Conclusion Combined measurement of serum HBV cccDNA, HBsAg, and HBV pgRNA has a good value in predicting the treatment outcome ofHBeAg-positive CHB patients treated with ETV.

     

  • [1] PAN HY, PAN HY, SONG WY, et al. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis[J]. J Viral Hepat, 2017,24(Suppl 1):29-35.
    [2] PAPATHEODORIDIS GV, SYPSA V, DALEKOS G, et al. Eightyear survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population[J].J Hepatol, 2018, 68(6):1129-1136.
    [3] Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8):1693-1701.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019, 35(8):1693-1701.
    [4] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association. Guidelines for the Prevention and treatment of chronic Hepatitis B(updated V2015)[J]. J Clin Hepatol, 2015, 31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015, 31(12):1941-1960.
    [5] YAO GB, REN H, XU DZ, et al. Continuous treatment of entecavir in patients with chronic hepatitis B for 3 years[J]. Chin J Hepatol, 2009,17(12):884-886.(in Chinese)姚光弼,任红,徐道振,等.慢性乙型肝炎患者持续应用恩替卡韦的疗效[J].中华肝脏病杂志,2009, 17(12):884-886.
    [6] VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. Optimal therapy of chronic hepatitis B:How do I treat HBeAg-positive patients?[J]. Liver Int, 2015, 35(Suppl 1):100-106.
    [7] GUO Y, LI Y, MU S, et al. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication[J]. J Med Virol, 2009, 81(7):1177-1183.
    [8] SPANGENBERG HC, THIMME R, BLUM HE. Tracking cccDNA in chronic HBV infection[J]. Hepatology, 2004, 39(6):1736-1738.
    [9] CHONG CL, CHEN ML, WU YC, et al. Dynamics of HBV cccDNA expression and transcription in different cell growth phase[J]. J Biomed Sci, 2011, 18:96.
    [10] WU M, LI J, YUE L, et al. Establishment of Cre-mediated HBV recombinant cccDNA(rcccDNA)cell line for cccDNA biology and antiviral screening assays[J]. Antiviral Res, 2018,152:45-52.
    [11] BUTLER EK, GERSCH J, MCNAMARA A, et al. Hepatitis B virus serum DNA andRNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection[J]. Hepatology, 2018, 68(6):2106-2117.
    [12] GAO N, WU RH, WANG XM, et al. Predictive value of HBsAg quantitative test for prognosis of patients with chronic severe hepatitis B[J]. J Clin Hepatol, 2016, 32(4):192-194.(in Chinese)高娜,吴瑞红,王晓美,等.HBsAg定量检测对慢性重型乙型肝炎患者预后的预测价值[J].临床肝胆病杂志,2016, 32(4):192-194.
    [13] ZHOU YQ, LI C. Value of HBsAg quantification in individualized anti-HBV treatment with nucleos(t)ide analogues[J]. J Clin Hepatol, 2019, 35(8):1821-1823.(in Chinese)周友乾,李翠.HBsAg定量在核苷(酸)类似物个体化抗HBV治疗中的应用价值[J].临床肝胆病杂志,2019, 35(8):1821-1823.
    [14] PENG H, WEI F, LIU JY, et al. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification:A meta-analysis[J]. Hepatol Int, 2015, 9(4):543-557.
    [15] van BOMMMEL F, BERG T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B[J]. Liver Int, 2018, 38(Suppl 1):90-96.
    [16] TAN N, LUO H, XU XY. Significance of hepatitis B virus pregenomic RNA in the progression of chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(10):2221-2223.(in Chinese)谭宁,罗皓,徐小元.HBV pgRNA在慢性乙型肝炎进程中的可能意义[J].临床肝胆病杂志,2018, 34(10):2221-2223.
    [17] ZHANG S, SUN J, XING HC. Progress on new anti-hepatitis B viral drugs[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2019, 13(1):6-11.(in Chinese)张珊,孙静,邢卉春.新型抗乙型肝炎病毒药物研究进展[J/CD].中华实验和临床感染病杂志(电子版),2019, 13(1):6-11.
    [18] CAREY I, GERSCH J, WANG B, et al. Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy[J]. Hepatology, 2019.[Online ahead of print].
    [19] YIN XR, FAN R, HOU JL. A 10-year prospective, random, observational study involving 24 countries in the world for long-term treatment of chronic hepatitis B with entecavir or other oral antiviral drugs[J]. J Clin Hepatol, 2019, 35(9):2005.(in Chinese)尹雪如,樊蓉,侯金林.一项为期10年、涉及全球24国的恩替卡韦或其他口服抗病毒药物长期治疗慢性乙型肝炎的前瞻性、随机、观察性研究结果[J].临床肝胆病杂志,2019, 35(9):2005.
  • Relative Articles

    [1]Xin SUN, Qiong LUO, Tao YANG, Chenghai. LIU. Management and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1538-1542. doi: 10.12449/JCH240806
    [2]Qinrong LI, Ying YAO, Zhiyuan XU. Research advances in drug-induced autoimmune-like hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1255-1258. doi: 10.12449/JCH240628
    [3]Ying LIU, Ping ZHU, Jing LIANG, Huiling XIANG. Value of total bilirubin rebound rate and total bilirubin clearance rate in evaluating the prognosis of severe drug-induced liver injury after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 606-612. doi: 10.3969/j.issn.1001-5256.2023.03.018
    [4]Jinsheng GUO. Prevention and treatment of indirect drug-induced liver toxicity[J]. Journal of Clinical Hepatology, 2022, 38(8): 1923-1926. doi: 10.3969/j.issn.1001-5256.2022.08.040
    [5]Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
    [6]Yu WANG, Qiong LUO, Shu LI, Xiaoping SHEN, Shuang LI, Yanyan TAO, Chenghai LIU. A preliminary study on the peripheral seroimmunological characteristics of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(5): 1097-1100. doi: 10.3969/j.issn.1001-5256.2022.05.023
    [7]Lu LI, Shuang LI, Yu CHEN. Pathogenesis of coronavirus disease 2019 with liver injury[J]. Journal of Clinical Hepatology, 2021, 37(1): 209-211. doi: 10.3969/j.issn.1001-5256.2021.01.046
    [8]Rongtao LAI, Qing XIE. Clinical features of drug-induced liver failure and related diagnosis and treatment strategies[J]. Journal of Clinical Hepatology, 2021, 37(11): 2534-2538. doi: 10.3969/j.issn.1001-5256.2021.11.006
    [9]Shiyuan CUI, Meifang ZHENG, Wei ZHANG, Shanshan WANG, Runping GAO. A case of autoimmune-like methimazole-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(12): 2896-2898. doi: 10.3969/j.issn.1001-5256.2021.12.032
    [10]Xiaoyun LI, Jieting TANG. Epidemiology of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2510-2514. doi: 10.3969/j.issn.1001-5256.2021.11.002
    [11]Shuai CHEN, Changqing YANG. Drug-induced liver injury: Advances and confusions in treatment[J]. Journal of Clinical Hepatology, 2021, 37(11): 2505-2509. doi: 10.3969/j.issn.1001-5256.2021.11.001
    [12]Ma WeiYu, Deng ZhiHua. Current status of immunogenetic studies on primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 932-935. doi: 10.3969/j.issn.1001-5256.2020.04.050
    [13]Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028
    [14]Tao LiNa, Qu XiaoYu, Zhang Yue, Song YanQing, Zhang SiXi. Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials[J]. Journal of Clinical Hepatology, 2019, 35(8): 1775-1781. doi: 10.3969/j.issn.1001-5256.2019.08.025
    [15]Jiang YingYing, Zhang XiaoHui, Zheng SuJun. Change in immune status after antiviral therapy in patients with hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2018, 34(2): 403-406. doi: 10.3969/j.issn.1001-5256.2018.02.041
    [16]Zhu JuanJuan, Cheng MingLiang, Zhao XueKe. Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 570-573. doi: 10.3969/j.issn.1001-5256.2016.03.038
    [17]Wang WeiBin, Li YongYin, Hou JinLin. Features of immune response during antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(10): 1858-1862. doi: 10.3969/j.issn.1001-5256.2016.10.007
    [18]Jia ZhanSheng, Lian JianQi. Improving understanding of liver immune function and enhancing research on cell therapy for liver diseases[J]. Journal of Clinical Hepatology, 2014, 30(9): 839-841. doi: 10.3969/j.issn.1001-5256.2014.09.001
    [19]Zhang Zheng, Wang FuSheng. Current perspectives on immune pathogenesis and immune therapy of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2012, 28(11): 801-804.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1458) PDF downloads(187) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return